PUR1500 is an experimental therapy in the discovery stage by Pulmatrix for the treatment of idiopathic pulmonary fibrosis (IPF). The therapy would be a kinase inhibitor with established anti-angiogenesis activity. The company aims to deliver PUR1500 in small, dense, and easily dispersible powdered form via Pulmatrix’s iSPERSE platform.

PUR1500 is still being assessed for formulation feasibility, which means that it may or may not progress to clinical-stage development.

How PUR1500 Works

PUR1500 may suppress the fibrotic pathway in the lungs’ interstitium. The interstitium is the tissue between the pulmonary alveoli and the bloodstream, where oxygen is transferred from the lungs to the blood.

Pulmatrix believes that by using its iSPERSE formulation technology, PUR1500 could be delivered in an effective therapeutic dose to suppress fibrosis, reduce systemic exposure of the drug, and lower side effects.

Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

  1. http://pulmatrix.com/pipeline.html
  2. https://radiopaedia.org/articles/pulmonary-interstitium
  3. http://ir.pulmatrix.com/news-releases?item=21
Özge has a MSc. in Molecular Genetics from the University of Leicester and a PhD in Developmental Biology from Queen Mary University of London. She worked as a Post-doctoral Research Associate at the University of Leicester for six years in the field of Behavioural Neurology before moving into science communication. She worked as the Research Communication Officer at a London based charity for almost two years.
Total Posts: 110
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
×
Özge has a MSc. in Molecular Genetics from the University of Leicester and a PhD in Developmental Biology from Queen Mary University of London. She worked as a Post-doctoral Research Associate at the University of Leicester for six years in the field of Behavioural Neurology before moving into science communication. She worked as the Research Communication Officer at a London based charity for almost two years.
Latest Posts
  • Fat-free mass index
  • acute exacerbation
  • lung function test
  • lung disease treatment